Systematic review & meta-analysis by @umichradiology on the risk of NSF in patients w stage 4 or 5 chronic kidney disease exposed to a group II GBCA https://t.co/16ZXMCoPXN
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @PrasadShankarMD: Our most recent MRQC effort, published in @JAMAInternalMed : https://t.co/dQDV5hq8rN 0/4931 cases of NSF in patients…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @hswapnil: Dept of confirmatory news H/t @petermagner2 SR on @JAMAInternalMed on class 2 Gd and risk of NSF https://t.co/Ce1OzG0aWT
RT @PrasadShankarMD: Our most recent MRQC effort, published in @JAMAInternalMed : https://t.co/dQDV5hq8rN 0/4931 cases of NSF in patients…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @brzoskos: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Ba…
Hugely important work from @PrasadShankarMD and @MattDavenportMD from @UMichRadiology, showing no NSF in nearly 5K patients with stage 4/5 CKD and who got a Group II GBCA. Major implications for patient care. https://t.co/WBfPhHodg9
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
Routine screening for renal failure when using a group II gadolinium agent is technically optional according to the ACR but the overwhelming evidence of the safety of these agents in chronic kidney disease suggest that some day (soon), routine screening wi
RT @hswapnil: Dept of confirmatory news H/t @petermagner2 SR on @JAMAInternalMed on class 2 Gd and risk of NSF https://t.co/Ce1OzG0aWT
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @PrasadShankarMD: Our most recent MRQC effort, published in @JAMAInternalMed : https://t.co/dQDV5hq8rN 0/4931 cases of NSF in patients…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
Risque quasi nul de fibrose néphrogénique après injection de gadolinium type II. Bon je crois que le débat est clos. https://t.co/0URiR1UaK1
RT @hswapnil: Dept of confirmatory news H/t @petermagner2 SR on @JAMAInternalMed on class 2 Gd and risk of NSF https://t.co/Ce1OzG0aWT
RT @PrasadShankarMD: Our most recent MRQC effort, published in @JAMAInternalMed : https://t.co/dQDV5hq8rN 0/4931 cases of NSF in patients…
This will make those calls about “can we do an MRI” easier to answer.
RT @hswapnil: Dept of confirmatory news H/t @petermagner2 SR on @JAMAInternalMed on class 2 Gd and risk of NSF https://t.co/Ce1OzG0aWT
RT @PrasadShankarMD: Our most recent MRQC effort, published in @JAMAInternalMed : https://t.co/dQDV5hq8rN 0/4931 cases of NSF in patients…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
New article: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis. https://t.co/wfBOrhrHFA #kidneycancer #oncology
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @hswapnil: Dept of confirmatory news H/t @petermagner2 SR on @JAMAInternalMed on class 2 Gd and risk of NSF https://t.co/Ce1OzG0aWT
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
Los daños diagnósticos potenciales de suspender el agente de contraste con gadolinio para los exámenes indicados podrían superar el riesgo de la fibrosis sistémica nefrogénica en los pacientes con nefropatía crónica estadío 4 o 5 https://t.co/eFrO1WtpWB
RT @PrasadShankarMD: Our most recent MRQC effort, published in @JAMAInternalMed : https://t.co/dQDV5hq8rN 0/4931 cases of NSF in patients…
RT @PrasadShankarMD: Our most recent MRQC effort, published in @JAMAInternalMed : https://t.co/dQDV5hq8rN 0/4931 cases of NSF in patients…
RT @arvindcanchi: So that's an NSF risk < 0.07% The name is Bond Bonded with data. https://t.co/f0iT16H80F
RT @brzoskos: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Ba…
RT @PrasadShankarMD: Our most recent MRQC effort, published in @JAMAInternalMed : https://t.co/dQDV5hq8rN 0/4931 cases of NSF in patients…
RT @PrasadShankarMD: Our most recent MRQC effort, published in @JAMAInternalMed : https://t.co/dQDV5hq8rN 0/4931 cases of NSF in patients…
RT @hswapnil: Dept of confirmatory news H/t @petermagner2 SR on @JAMAInternalMed on class 2 Gd and risk of NSF https://t.co/Ce1OzG0aWT
RT @PrasadShankarMD: Our most recent MRQC effort, published in @JAMAInternalMed : https://t.co/dQDV5hq8rN 0/4931 cases of NSF in patients…
RT @PrasadShankarMD: Our most recent MRQC effort, published in @JAMAInternalMed : https://t.co/dQDV5hq8rN 0/4931 cases of NSF in patients…
RT @PrasadShankarMD: Our most recent MRQC effort, published in @JAMAInternalMed : https://t.co/dQDV5hq8rN 0/4931 cases of NSF in patients…
RT @hswapnil: Dept of confirmatory news H/t @petermagner2 SR on @JAMAInternalMed on class 2 Gd and risk of NSF https://t.co/Ce1OzG0aWT
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @PrasadShankarMD: Our most recent MRQC effort, published in @JAMAInternalMed : https://t.co/dQDV5hq8rN 0/4931 cases of NSF in patients…
RT @PrasadShankarMD: Our most recent MRQC effort, published in @JAMAInternalMed : https://t.co/dQDV5hq8rN 0/4931 cases of NSF in patients…
Are you going to give contrast to your end stage renal patients for work up or treatment planning?
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @PrasadShankarMD: Our most recent MRQC effort, published in @JAMAInternalMed : https://t.co/dQDV5hq8rN 0/4931 cases of NSF in patients…
So that's an NSF risk < 0.07% The name is Bond Bonded with data.
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nephrogenic systemic fibrosis (NSF) in patients with eGFR<30 (CKD 4 or 5) to be 0%, with a 95% CI upper bound of 0.07%. https://t.co/g
RT @PrasadShankarMD: Our most recent MRQC effort, published in @JAMAInternalMed : https://t.co/dQDV5hq8rN 0/4931 cases of NSF in patients…
RT @PrasadShankarMD: Our most recent MRQC effort, published in @JAMAInternalMed : https://t.co/dQDV5hq8rN 0/4931 cases of NSF in patients…
Risks of withholding GAD in stage 4/5 CKD may be greater than the risks of giving it
RT @PrasadShankarMD: Our most recent MRQC effort, published in @JAMAInternalMed : https://t.co/dQDV5hq8rN 0/4931 cases of NSF in patients…
RT @PrasadShankarMD: Our most recent MRQC effort, published in @JAMAInternalMed : https://t.co/dQDV5hq8rN 0/4931 cases of NSF in patients…
RT @PrasadShankarMD: Our most recent MRQC effort, published in @JAMAInternalMed : https://t.co/dQDV5hq8rN 0/4931 cases of NSF in patients…
RT @PrasadShankarMD: Our most recent MRQC effort, published in @JAMAInternalMed : https://t.co/dQDV5hq8rN 0/4931 cases of NSF in patients…
RT @PrasadShankarMD: Our most recent MRQC effort, published in @JAMAInternalMed : https://t.co/dQDV5hq8rN 0/4931 cases of NSF in patients…
NSF risk in CKD https://t.co/3a2Lsmoia8 @JAMAInternalMed
RT @PrasadShankarMD: Our most recent MRQC effort, published in @JAMAInternalMed : https://t.co/dQDV5hq8rN 0/4931 cases of NSF in patients…
RT @PrasadShankarMD: Our most recent MRQC effort, published in @JAMAInternalMed : https://t.co/dQDV5hq8rN 0/4931 cases of NSF in patients…
RT @PrasadShankarMD: Our most recent MRQC effort, published in @JAMAInternalMed : https://t.co/dQDV5hq8rN 0/4931 cases of NSF in patients…
RT @hswapnil: Dept of confirmatory news H/t @petermagner2 SR on @JAMAInternalMed on class 2 Gd and risk of NSF https://t.co/Ce1OzG0aWT
Where I've practiced the fear of NSF in CKD 4/5 dominates. The absolute risk of this horrible skin complication is <0.07%!!! If needing an MRI to dictate care (ie findings would change practice), benefits will likely outweigh risks in most situations
RT @PrasadShankarMD: Our most recent MRQC effort, published in @JAMAInternalMed : https://t.co/dQDV5hq8rN 0/4931 cases of NSF in patients…
So the risk of NSF in CKD 4/5 is 0.07%. Is it now the risk of not doing the MR with contrast greater? #FOAMed #FOAMrad #neph #askrenal Risk of NSF in Stage 4 or 5 CKD After Group II Gadolinium-Based Contrast Agent Receipt https://t.co/2pNM1Q
RT @saugarmaripuri: And our editorial to this important study https://t.co/YPOGKWkfUD https://t.co/uUHXHtuujP
RT @saugarmaripuri: And our editorial to this important study https://t.co/YPOGKWkfUD https://t.co/uUHXHtuujP
And our editorial to this important study https://t.co/YPOGKWkfUD
RT @hswapnil: Dept of confirmatory news H/t @petermagner2 SR on @JAMAInternalMed on class 2 Gd and risk of NSF https://t.co/Ce1OzG0aWT
Dept of confirmatory news H/t @petermagner2 SR on @JAMAInternalMed on class 2 Gd and risk of NSF https://t.co/Ce1OzG0aWT
Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis | Chronic Kidney Disease | JAMA Internal Medicine | JAMA Network https://